undamentalytics Newsletter
Sign in

Fennec Pharmaceuticals Inc. income statement

In fiscal 2025, Fennec Pharmaceuticals Inc. reported revenue of $44.6m, down 6.1% on the year before, operating income of −$6.3m (a -14.1% margin) and net income of −$9.7m, or −$0.34 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0000000000221484559
Cost of revenue——————————01———
Gross profit——————————120———
Research and development121000256540000
Selling and marketing——————————312181933
General and administrative221322557131821232823
Operating income−3−4−2−3−2−3−7−10−13−18−23−133−6−1
Interest expense000————————3421
Net interest income——————————00———
Income before tax——2−2−1−3−7————−16−0−10—
Income tax—0000000000—00—
Net income5−52−2−1−3−7−10−13−18−24−16−0−10−3
Diluted EPS$0.19−$0.21$0.17−$0.22−$0.06−$0.22−$0.47−$0.52−$0.64−$0.76−$0.90−$0.60−$0.02−$0.34−$0.10
Diluted shares (average)24m25m11m10m11m13m15m19m20m24m26m27m27m29m33m
EBITDA−3−4−2————————————

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: FENC vs NTLAFENC vs IVVDFENC vs NKTR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Fennec Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Fennec Pharmaceuticals Inc.